Navigation Links
Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
Date:2/11/2013

YORK, Pa., Feb. 11, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ:  UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2012, (the second quarter of Fiscal Year 2013).

Highlights for the Fiscal Year 2013 Second Quarter:

  • In November 2012, Unilife announced that its platform of bolus injection devices had been selected by a global pharmaceutical company to enter a final stage of evaluation as its preferred choice for use in a multi-drug program. Unilife's bolus injectors have also been selected by many other pharmaceutical companies for targeted use with late-stage pipeline drugs. Negotiations for agreements are underway in each case.
  • In December 2012, Unilife announced that a U.S. based pharmaceutical company has commenced stability and evaluation studies of the Unifill® syringe for use with multiple injectable drugs.  The target drugs, which include both pipeline drugs as well as commercially approved drugs that will benefit from lifecycle extension, are high-value therapeutics for chronic diseases and require periodic injections.
  • Unilife continued to supply initial batches of Unifill syringes to many pharmaceutical companies that are in various stages of evaluating its use for a range of approved and late-stage pipeline drugs. In addition to prospective supply and clinical development contracts, we expect other customers to enter their drugs into stability studies with Unifill this calendar year.
  • Unilife announced the development of its Depot-Ject™ and Unilife Ocu-Ject™ platforms for the targeted delivery of drugs to specific regions of the body such as the eye. These high-precision drug delivery platforms are now being pursued by multiple interested parties.
  • The RITA™ disposable auto-injectors and LISA™ reusable auto-injectors were supplied to a number of pharmaceutical companies for evaluation and user studies. Unilife has been advised that these evaluations are progressing favorably.
  • The Unilife EZMix™ drug reconstitution system was selected by a pharmaceutical company for use with a late-stage pipeline drug. Negotiations for an EZMix supply contract with this company are underway.
  • Unilife expanded its commercial development team with the appointment of Douglas Stout, Derek Giersch, Joseph Crusco as Senior Directors of Commercial Development; and Jashin Gugnani as Director of Commercial Development in October 2012; as well as the appointment of Glenn Thorpe as Vice-President of Commercial Development in February 2013.

    • "During the quarter, we were pleased to provide shareholders with greater insight into the size and scope of our commercial pipeline," stated Mr. Alan Shortall, CEO of Unilife. "Out of 31 active programs selected from our deep and rapidly expanding commercial pipeline, we expect several to generate initial revenues during calendar year 2013.  Given the size and long-term nature of many of these prospective agreements, we are confident they will underpin our future success.

    "Over the last few weeks, we raised approximately $13.4 million in net equity capital, which has strengthened our balance sheet as we look to finalize several commercial supply contracts and clinical development agreements.  We are also working to conclude discussions with U.S. institutions to secure long-term debt financing that will support the Company's operational activities and minimize dilution for the foreseeable future," Mr. Shortall concluded.

    Financial Results for Three Months Ended December 31, 2012
    Revenues for the three months ended December 31, 2012, were $0.7 million compared to $0.9 million for the same period in 2011. The Company's net loss for the three months ended December 31, 2012, was $14.6 million, or $0.19 per share, compared to a net loss of $12.9 million, or $0.19 per share, for the same period in 2011. The increase in the net loss was primarily attributable to the decrease in revenue and an increase in non-cash share-based compensation expenses.

    Adjusted net loss for the three months ended December 31, 2012, was $9.7 million, or $0.12 per share, compared to $9.6 million, or $0.14 per share, for the same period in 2011. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense.

    Unilife had $8.3 million of total cash, including restricted cash, as of December 31, 2012, which does not reflect the $3.8 million in net proceeds the Company received from the implementation of its At-the-Market (ATM) facility with Cantor Fitzgerald in January 2013; or the $9.6 million in net proceeds the Company received from a common stock offering with a U.S. based institutional investor in February 2013. 

    Conference Call Information
    Management has scheduled a conference call for 4:30 p.m. U.S. EST on Monday, February 11, 2013 (Tuesday, February 12, 2013 at 8:30 a.m. AEDT), to review the Company's financial results, market trends and future outlook.  The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen only Webcast.  An archive of the presentation and webcast will be available for 30 days after the call.  To listen, please go to: http://ir.unilife.com/events.cfm.About Unilife Corporation
    Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, bolus injection devices and targeted delivery systems. Each of these innovative and highly differentiated device platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

    Forward-Looking Statements
    This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

    Non-GAAP Financial Measures
    U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure.  The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures.  Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

    Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results.  Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.  A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.

    General: UNIS-G Investor Contacts (US):
    Analyst EnquiriesInvestor Contacts (Australia)Todd Fromer / Garth RussellLynn PieperJeff CarterKCSA Strategic CommunicationsWestwicke PartnersUnilife CorporationP: + 1 212-682-63P: + 1 415-202-5678P: + 61 2 8346 6500 (Tables Below) UNILIFE CORPORATION AND SUBSIDIARIES Consolidated Balance Sheets (unaudited) December 31, 2012June 30, 2012(in thousands, except share data)AssetsCurrent Assets:Cash and cash equivalents$
    5,914

    $
    ,410Restricted cash2,400

    2,400Accounts receivable104

    1,042Inventories156

    212Prepaid expenses and other current assets

    714

    676Total current assets9,288

    15,740Property, plant and equipment, net51,375

    52,514Goodwill12,993

    12,734Intangible assets, net31

    34Other assets1,275

    1,286Total assets 

    $
    74,962

    $
    82,308Liabilities and Stockholders' EquityCurrent Liabilities:Accounts payable

    $
    ,845

    $
    2,399Accrued expenses

    2,430

    2,209Current portion of long-term debt5,804

    5,655Deferred revenue2,649

    2,595Total current liabilities12,728

    12,858Long-term debt, less current portion20,615

    23,110Deferred revenue1,374

    2,595Total liabilities34,717

    38,563Stockholders' Equity:Preferred stock, $0.01 par value, 50,000,000 shares authorized as of December 31, 2012; none issued or outstanding as of December 31, 2012 and June 30, 2012—

    —Common stock, $0.01 par value, 250,000,000 shares authorized as of December 31, 2012; 83,288,081 and 75,849,439 shares issued, and 83,259,411 and 75,820,769 shares outstanding as of December 31, 2012 and June 30, 2012, respectively

    833

    758Additional paid-in-capital235,720

    212,326Accumulated deficit(199,771 )

    (172,634 )Accumulated other comprehensive income

    3,603

    3,435Treasury stock, at cost, 28,670 shares as of December 31, 2012 and June 30, 2012(140 )

    (140 )Total stockholders' equity 

    40,245

    43,745Total liabilities and stockholders' equity 

    $
    74,962

    $
    82,308 UNILIFE CORPORATION AND SUBSIDIARIESConsolidated Statements of Operations(unaudited) Three Months EndedSix Months EndedDecember 31,December 31,2012201120122011(in thousands, except per share data)Revenues:Industrialization and development fees

    $
    8212;$
    249$
    8212;$
    ,689Licensing fees

    6636461,3261,318Product sales and other

    36176535Total revenues

    6999121,3913,042Cost of product sales

    22168190Gross profit

    6778961,3102,952Operating expenses:Research and development

    4,9945,2629,7329,560Selling, general and administrative

    8,3276,71214,90412,895Depreciation and amortization

    1,3651,1572,5882,150Total operating expenses

    14,68613,13127,22424,605Operating loss

    (14,009)(12,235)(25,914)(21,653)Interest expense

    6456391,261922Interest income

    (14)(26)(38)(56)Other expense, net

    —2—36Net loss

    $
    (14,640)$
    (12,850)$
    (27,137)$
    (22,555)Net loss per share:Basic and diluted net loss per share

    $
    (0.19)$
    (0.19)$
    (0.35)$
    (0.35) UNILIFE CORPORATION AND SUBSIDIARIES Reconciliation of Non-GAAP Measure(unaudited)  Three Months EndedSix Months EndedDecember 31,December 31,2012201120122011(in thousands, except per share data)Net loss

    $
    (14,640)$
    (12,850)$
    (27,137)$
    (22,555)Share-based compensation expense

    2,9631,4854,5183,385Depreciation and amortization

    1,3651,1572,5882,150Interest expense

    6456391,261922Adjusted net loss

    $
    (9,667)$
    (9,569)$
    (18,770)$
    (16,098)Adjusted net loss per share – diluted

    $
    (0.12)$
    (0.14)$
    (0.24)$
    (0.25) 

     


    '/>"/>
    SOURCE Unilife Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Related medicine technology :

    1. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
    2. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
    3. Unilife Corporation to Announce Financial Results for Fiscal 2012 Fourth Quarter and Year End on Monday, July 30, 2012
    4. Unilife Corporation Announces Financial Results For Fiscal Year 2012 Fourth Quarter
    5. Griffin Securities Analyst Interviews Unilife Corp. CEO in a Two-Part Video Series
    6. Unilife Corporation To Announce Financial Results For Fiscal 2013 First Quarter On Tuesday, October 30, 2012
    7. Second Part of the Griffin Securities Analyst Interview with Unilife Corp. CEO is Now Available
    8. Unilife Corporation Reschedules Release Of Quarterly Results And Earnings Call Due To Severe Weather In Northeastern U.S.
    9. Unilifes Bolus Injector Platform Targeted by Global Pharmaceutical Company for Use in Multi-Drug Program
    10. Unilife Corporation Announces Financial Results For Fiscal Year 2013 First Quarter
    11. Unilife to Present at the Lazard 9th Annual Healthcare Conference in New York City on November 13th
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/12/2017)... , Oct. 12, 2017   Divoti USA ... Jewelry up to the standard of the latest FDA requirements, which ... 2017). Anyone in need of Medical ID jewelry such ... Alert Jewelry are engraved in terms of the new ... Divoti offers ...
    (Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
    (Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
    (Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
    (Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
    (Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
    Breaking Medicine News(10 mins):